<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395612</url>
  </required_header>
  <id_info>
    <org_study_id>CQGOG0101</org_study_id>
    <nct_id>NCT04395612</nct_id>
  </id_info>
  <brief_title>Niraparib Combined With Brivanib in Patients With Cervical Cancer</brief_title>
  <acronym>CQGOG0101</acronym>
  <official_title>A Clinical Proof-of-concept and Safety Study Evaluating ZL-2306 (Niraparib) Combined With Brivanib in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing University Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing University Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical proof-of-concept and safety study evaluating ZL-2306 (niraparib) combined with
      brivanib in patients with metastatic, recurrent, and persistent cervical cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, open-ended, single-arm, phase II clinical study.Patients are with metastatic,
      recurrent, persistent cervical cancer (squamous cell carcinoma, adenocarcinoma, adenosquamous
      carcinoma) To observe the efficacy and safety of ZL-2306 (niraparib) combined with brivanib
      in patients with metastatic, recurrent and persistent cervical cancer, and to explore the
      biomarkers of effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
    <description>Objective To evaluate the objective response rate (CR + PR) of ZL-2306 (niraparib) and brivanib in patients with relapsed and persistent cervical cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>6 months</time_frame>
    <description>progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>6 months</time_frame>
    <description>evaluate the safety of combined application of ZL-2306 (niraparib) and brivanib, disease control rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>niraparib200mg，brivanib600mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib200mg and Brivanib600mg</intervention_name>
    <description>Niraparib 200mg and Brivanib 600mg</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Treatment group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1.Female, aged ≥ 18 yrs and ≤70 yrs; 2.Patients volunteered to participate in this study,
        signed informed consent, good compliance, and cooperated with follow-up; 3.The subjects'
        damage caused by other treatments has been recovered (NCI CTCAE version 5.0 grade ≤ grade
        1), ECOG score ≤ 2 points 4.Expected survival is longer than 3 months; 5.Pathological
        diagnosis of cervical squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma;
        6.Evaluable lesions: CT scan of tumor lesions ≥5mm in length, CT scan of lymph node lesions
        ≥10mm in length, and scan layer thickness not greater than 5mm (refer to RECIST 1.1); 7.The
        first diagnosis was confirmed by pathology and / or cytology to be metastatic, or
        recurrent, persistent cervical cancer (mainly refers to tumors remaining or progressing at
        least 3 months after initial radiotherapy or concurrent chemoradiotherapy), and the patient
        can no longer accept Surgery or chemoradiation; 8.Subject agrees to take blood sample;
        9.Subjects can provide formalin-fixed, paraffin-embedded tumor tissue samples for
        subsequent related gene testing (optional); 10.A.Complete blood count: hemoglobin (Hb)
        ≥90g/L ; absolute neutrophil count (ANC) ≥1.0×109/L ; platelets &gt;=100×109/L B. Biochemical
        test standards: a. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2
        times the upper limit of normal value (ULN). If with liver metastases, ALT and AST ≤ 5 ×
        ULN; b. Total bilirubin (TBIL) ≤ 1.5 × ULN; c. Serum creatinine (Cr) ≤ 1.5 × ULN or
        creatinine clearance (CCr) ≥ 60ml / min; d. Doppler ultrasound evaluation: left ventricular
        ejection Blood fraction (LVEF) ≥ the lower limit of normal value (50%).

        11.Women of childbearing age should agree that contraception (such as an intrauterine
        device, contraceptive, or condom) must be used during the study and within 3 months after
        the last dose; a serum or urine pregnancy test must be negative within 14 days of study
        enrollment and must be Non-lactating patients. Sign written informed consent before
        conducting any research-related procedures.

        Exclusion Criteria:

          -  1.People who are known to be allergic to zl-2306 (niraparib) or to active or inactive
             ingredients of drugs with similar chemical structures to zl-2306 (niraparib).

             2.Multiple factors affecting oral medication (such as inability to swallow,
             post-gastrointestinal resection, chronic diarrhea, etc.).

             3.People who are known to be allergic to brivanib or to an active or inactive
             component of a drug with a similar chemical structure to brivanib.

             4.Symptomatic, uncontrolled brain metastases or pia meningeal metastases. No imaging
             scan is required to confirm brain-free metastases; patients with spinal cord
             compression may still be considered if they have received targeted treatment and have
             evidence of clinical stability of the disease for at least&gt; 28 days (controlled
             central nervous system metastasis must be in the study Have received treatment such as
             radiation or chemotherapy for at least 1 month; patients must not have new symptoms
             related to central nervous system lesions or symptoms that indicate disease
             progression, and patients either take a stable dose of hormones or do not need to take
             hormones).

             5.Underwent major surgery within 3 weeks before the study began, or any surgical
             effects that have not recovered after surgery, or received chemotherapy.

             6.Received&gt; 20% bone marrow palliative radiotherapy 1 week before enrollment. 7.Have
             aggressive cancers other than cervical cancer (except fully treated basal or squamous
             cell skin cancer within 2 years before enrollment).

             8.Patient has a previous or current diagnosis of myelodysplastic syndrome (MDS) or
             acute myeloid leukemia (AML).

             9.Suffering from a serious or uncontrolled illness, including but not limited to:

               1. Uncontrollable nausea and vomiting, inability to swallow research drugs, and any
                  gastrointestinal disorders that may interfere with the metabolism of the drug.

               2. Active viral infections such as human immunodeficiency virus, hepatitis B,
                  hepatitis C, etc.

               3. Uncontrolled major seizures, unstable spinal cord compression, superior vena cava
                  syndrome, or other mental illnesses that prevent patients from signing informed
                  consent.

               4. Immunodeficiency (except splenectomy), or other diseases that the investigator
                  believes may expose patients to high-risk toxicity.

                  10.History of bleeding and thrombosis:

               1. Any CTCAE Grade 2 bleeding event within 3 months prior to screening, or CTCAE
                  Grade 3 and above bleeding events within 6 months prior to screening.

               2. History of gastrointestinal bleeding or clear gastrointestinal bleeding tendency
                  within 6 months before screening. Such as: esophageal varices at risk of
                  bleeding, focal lesions of locally active ulcers, or fecal occult blood +.

               3. Have active bleeding or coagulopathy, have a tendency to bleed, or are receiving
                  thrombolytic or anticoagulant therapy.

               4. Patients need anticoagulation with drugs such as warfarin or heparin.

               5. Patients need long-term antiplatelet therapy (eg aspirin, clopidogrel).

               6. Thrombosis or embolism events in the past 6 months, such as: cerebrovascular
                  accidents (including transient ischemic attacks), pulmonary embolism.

                  11.Serious cardiovascular history:

               1. NYHA (New York Heart Association) Grade 3 and 4 congestive heart failure.

               2. Suffering from unstable angina or newly diagnosed angina or myocardial infarction
                  within 12 months before screening.

               3. Arrhythmias requiring therapeutic intervention (patients taking beta-blockers or
                  digoxin can be enrolled).

               4. CTCAE≥ grade 2 valvular heart disease.

                  12.Poorly controlled hypertension (systolic blood pressure&gt; 150 mmHg or diastolic
                  blood pressure&gt; 100 mmHg).

                  13.Other laboratory inspection abnormalities:

               1. Hyponatremia (sodium &lt;130 mmol / L); baseline serum potassium &lt;3.5 mmol / L
                  (before entering the study, potassium supplements can be used to restore serum
                  potassium above this level).

               2. Abnormal thyroid function, and drugs cannot maintain thyroid function within
                  normal range.

                  14.Any previous or current disease, treatment, or laboratory abnormality that may
                  interfere with the results of the study, affect the patient's full participation
                  in the study, or the investigator believes that the patient is not suitable to
                  participate in the study; the patient may not receive platelets within 4 weeks
                  before the study drug begins Red blood cell infusion.

                  15.Patients who are pregnant or breastfeeding, or plan to become pregnant during
                  study treatment.

                  16.Corrected QTc interval (QTc)&gt; 450 milliseconds; if the patient has a prolonged
                  QTc interval, but the investigator evaluates that the reason for the prolongation
                  is a pacemaker (and no other cardiac abnormalities), it is necessary to discuss
                  with the investigator to determine whether the patient is suitable Group study.

                  17.Have previously received any PARP inhibitor treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi Zhou, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi Zhou, Ph.D.</last_name>
    <phone>13708384529</phone>
    <email>qizhou9128@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhou, PhD</last_name>
      <email>qizhou9128@163.com</email>
    </contact>
    <investigator>
      <last_name>Qi Zhou, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.</citation>
    <PMID>27717299</PMID>
  </reference>
  <results_reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen WQ, Li H, Sun KX, Zheng RS, Zhang SW, Zeng HM, Zou XN, Gu XY, He J. [Report of Cancer Incidence and Mortality in China, 2014]. Zhonghua Zhong Liu Za Zhi. 2018 Jan 23;40(1):5-13. doi: 10.3760/cma.j.issn.0253-3766.2018.01.002. Chinese.</citation>
    <PMID>29365411</PMID>
  </results_reference>
  <results_reference>
    <citation>Eskander RN, Tewari KS. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015 Jan 1;37(1):20-38. doi: 10.1016/j.clinthera.2014.11.010. Review.</citation>
    <PMID>25592089</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005 Sep;5(9):689-98. Review.</citation>
    <PMID>16110319</PMID>
  </results_reference>
  <results_reference>
    <citation>Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A, Xu JM. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2013 Apr 3;32:16. doi: 10.1186/1756-9966-32-16.</citation>
    <PMID>23552472</PMID>
  </results_reference>
  <results_reference>
    <citation>Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014 Nov;19(11):1156-68. doi: 10.1634/theoncologist.2014-0032. Epub 2014 Oct 17.</citation>
    <PMID>25326159</PMID>
  </results_reference>
  <results_reference>
    <citation>Fakhrejahani E, Toi M. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Jpn J Clin Oncol. 2014 Mar;44(3):197-207. doi: 10.1093/jjco/hyt201. Epub 2014 Jan 27. Review.</citation>
    <PMID>24474817</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing University Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Qi Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cervical Cancer Niraparib Brivanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

